Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET) Radiopharmaceutical Market Report 2026

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size has grown strongly in recent years. It will grow from $6.53 billion in 2025 to $7.04 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising prevalence of cancer and cardiovascular diseases, growth in nuclear medicine infrastructure, increasing demand for functional imaging techniques, advancements in radiopharmaceutical development, expansion of diagnostic imaging centers.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size is expected to see strong growth in the next few years. It will grow to $9.62 billion by 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized diagnostic solutions, growth in theranostics applications, rising investment in nuclear medicine research, advancements in radioisotope production technologies, expanding use of pet imaging in clinical practice. Major trends in the forecast period include increasing adoption of targeted radiopharmaceuticals for disease-specific imaging, growing demand for hybrid imaging techniques combining spect and pet modalities, rising use of short half-life isotopes for improved safety and imaging precision, expansion of radiopharmaceutical applications in oncology and neurology, increasing focus on early disease detection and functional imaging.

The increasing prevalence of cancer is anticipated to drive the expansion of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market going forward. Cancer refers to a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body, which can develop into tumors and disrupt normal physiological functions. The incidence of cancer is rising due to an aging population, as elderly individuals are more likely to accumulate genetic mutations that may lead to uncontrolled cell growth. SPECT and PET radiopharmaceuticals allow highly sensitive and accurate visualization of tumors, enabling early cancer detection, precise staging, monitoring of treatment response, and support for personalized therapy decisions. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected in 2050, representing a 77% rise compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is fueling the growth of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market.

Leading companies operating in the positron emission tomography (PET) radiopharmaceutical market are focusing on developing innovative products such as cardiac positron emission tomography (PET) tracers to improve diagnostic accuracy and accessibility in coronary artery disease imaging. Cardiac positron emission tomography (PET) tracers are radioactive compounds used in PET imaging to visualize blood flow and detect areas of reduced perfusion in the heart, helping clinicians accurately diagnose coronary artery disease and assess myocardial ischemia and infarction in a noninvasive and highly sensitive manner. For example, in September 2024, GE HealthCare, a U. S. -based medical technology and pharmaceutical diagnostics company, received U. S. Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F 18), a cardiac PET (positron emission tomography) tracer for myocardial perfusion imaging (MPI) in patients with known or suspected coronary artery disease. Flyrcado is a ready-to-use unit dose radiotracer with a long half-life of 109 minutes, enabling high-resolution PET imaging, exercise stress testing, and rescans in the same session, improving diagnostic accuracy compared to traditional SPECT MPI agents. This approval expands access to advanced cardiac PET imaging, particularly benefiting difficult-to-image patients such as women and those with high body mass index (BMI).

In January 2026, SHINE Technologies LLC, a US-based healthcare technology and nuclear medicine production company, acquired the SPECT business of Lantheus Holdings for an undisclosed amount. With this acquisition, SHINE intends to enhance its capabilities and strengthen its market presence in nuclear medicine by taking over established SPECT diagnostic products and manufacturing operations while maintaining continuity and supporting the continued growth of the business. Lantheus Holdings Inc. is a US-based healthcare technology company that specialized in offering SPECT radiopharmaceutical diagnostic agents and related manufacturing operations used in single photon emission computed tomography imaging.

Major companies operating in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S. A., Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, Eczacıbaşı-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company.

North America was the dominating region in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market consists of sales of products such as diagnostic radiotracers, therapeutic radiopharmaceuticals, and radionuclide compounds such as technetium-99m, fluorine-18, and iodine-131. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.